Skip to Content

Premier Biomedical Announces Therapeutic Advance in the Treatment and Prevention of Suicide and Depression

ST. PETERSBURG, Fla., Dec. 18, 2012 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced a major achievement in its effort to develop a therapy for suicidal ideation and clinical depression. Premier Biomedical, Inc., which to date has achieved promising and innovative successes against cancer without application of any medication, was successful in removing the majority of target antigens associated with these two depressive disorder diseases from a heterogeneous mixture in the laboratory.

Mitchell S. Felder , M.D., Chairman of the Scientific Advisory Board of Premier Biomedical, Inc. stated, "Major Depressive Disorder is a disabling condition that adversely affects a person's family, work or school life, sleeping and eating habits, and general health. In the United States, up to thirty percent of primary care patients have been shown to have clinical depression, and it is estimated that 3% of people with major depression commit suicide. Our research has shown that we can completely remove the majority of inflammatory cytokines implicated in the etiology of major depression. This could be a major breakthrough against this affliction."

One of these inflammatory cytokines was a specified Interleukin, which had already been successfully removed by Premier Biomedical with a picogram level of accuracy (a picogram is a trillionth of a gram). It has been found in multiple published medical articles that a strong correlation exists between the concentration of specified interleukins in the spinal fluid and the severity of the patient's depression.

Premier CEO William A. Hartman expects that these successes will result in greater interest from researchers within the US Military. He commented, "It is a horrible tragedy what is happening to our returning veterans. Through 2012, it has been estimated that there have been more deaths from suicide than from combat. We'll do everything within our power to see that these returning young men and women get the best technological treatment they deserve."

"The next step will be to remove the targeted cytokines from Cerebrospinal Fluid," Hartman continued. "We are continuing proof-of-concept testing of Premier's technology for Alzheimer's disease, atherosclerosis, and traumatic brain injury (TBI), and proceeding with in-vivo tests for cancer."

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/ Lou Gehrig 's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.


Premier Biomedical, Inc.
William A. Hartman , CEO
(814) 786-8849

SOURCE Premier Biomedical, Inc.



Posted: December 2012